Peptic Ulcer Drugs Market Size to Reach USD 5.13 Billion by 2027; Increasing Adoption of OTC Drugs to Aid Growth

The global peptic ulcer drugs market size is expected to gain momentum by reaching USD 5.13 billion by 2027 owing to the increasing demand for over-the-counter (OTC) drugs and the increasing focus on developing strong peptic ulcer drugs during the forecast period. This information is published by Fortune Business Insights, in its latest report, titled, “Peptic Ulcer Drugs Market Size, Share & COVID-19 Impact Analysis, By Drugs Type (Proton Pump Inhibitor (PPI), H2 Antagonists, Antibiotics, and Others), By Ulcer Type (Gastric Ulcer and Duodenal Ulcer), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027.” The report further observes that the market was worth USD 4.25 billion in 2019 and is likely to exhibit a CAGR of 2.4% between 2020 and 2027.

Zydus Cadila Receives US FDA Approval for Misoprostol

In July 2019, Zydus Cadila, a global pharmaceutical company, announced the approval from the U.S. Food and Drug Administration to market the Misoprostol tablets. These tablets are available in a proportion of 100 mcg and 200 mcg. They are used to treat stomach ulcers in patients. In addition to this, they aid in decreasing the risk of contracting serious ulcer complications that include severe bleeding. According to the company, the drug is expected to be manufactured at the facility located at SEZ in Ahmedabad, India.

The group since the commencement of the filing process in the FY 2003-04, has secured over 268 approvals, along with filing over 360 ANDAs. The company is dedicated to create an extensive healthcare system and develop effective ulcer drugs that benefit patients largely. Such initiatives by companies such as Zydus are expected to aid in the expansion of the global market during the forecast period.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/peptic-ulcer-drugs-market-103483

Increasing Demand for OTC Peptic Ulcer Drugs to Favor Growth

The increasing prevalence of peptic ulcer disease is propelling the demand for novel peptic ulcer drugs. Key players are introducing several over-the-counter (OTC) drugs for the treatment of the disease that will favor the market growth. For instance, in February 2018, Strides Shasun, a leading provider of Ranitidine, announced the launch of the OTC drug version of Ranitidine to treat gastric ulcer in the U.S. The OTC drugs further provide cheaper and faster access to healthcare solution in treating the disease and therefore, the increasing adoption of these drugs will contribute to the global market growth during the forecast period.

Increasing Emphasis on R&D Activities by Major Companies to Hold Significant Market Shares

Pfizer, Inc., and AstraZeneca hold the highest share in the global peptic ulcer drugs market owing to their diverse product portfolios and a strong distribution network. These companies are investing in R&D activities to develop new peptic ulcer drugs and maintain dominance in the global marketplace. The other players are engaging in collaboration, merger and acquisition, and partnership strategies to aim for a considerable position in the market in the forthcoming years.

Industrial Development:

• July 2019: ANI Pharmaceuticals announced its partnership with Appco Pharma. This partnership is aimed at jointly launching generic ranitidine capsules for treating patients suffering from duodenal ulcers.

List of the Companies Operating in the Global Market

• AstraZeneca (Cambridge, United Kingdom)
• Novartis AG (Basel, Switzerland)
• Pfizer Inc. (New York, United States)
• GlaxoSmithKline plc. (Brentford, United Kingdom)
• Takeda Pharmaceutical Company Limited. (Tokyo, Japan)
• Mylan Pharmaceuticals Inc. (Canonsburg, Pennsylvania, United States)
• Abbott (Illinois, United States)
• Zydus Cadila (Gujrat, India)
• Other Players

Further Report Findings:

• North America was valued at USD 1.76 billion in 2019 and is expected to remain at the forefront by holding the highest global peptic ulcer drugs market share during the forecast period. This is attributable to the increasing prevalence of peptic ulcer disease that propels the demand for these ulcer drugs in the region.
• Europe, on the other hand, is expected to hold the second position in the market owing to the rising expenditure for healthcare in countries such as France, Germany, and the U.K. between 2020 and 2027.
• The segment antibiotics, based on drug type, held a market share of about 42.1% in 2019 and is expected to showcase significant growth in the forthcoming years. This is ascribable to factors such as the increasing cases of Helicobacter pylori (H.pylori) infection that is further driving the demand for antibiotics for treating patients.

Table of Segmentation: